Lead Pharma Holding BV is known for developing innovative small-molecule drugs for diagnosing autoimmune diseases and cancer. The company has created a versatile, proprietary drug design forum for attractive new compounds against drug those that need intense R&D expertise. SANOFI, on the other hand, functions as a pharmaceutical company. The Company manufactures prescription pharmaceuticals and vaccines. Sanofi also develops cardiovascular, thrombosis, metabolic disorder, central nervous system, and oncology medicines and drugs. Sanofi serves customers worldwide.
In India, the research of SANOFI focuses on prodrugs comprising a GLP-1/glucagon dual agonist linker hyaluronic acid conjugate, conjugates comprising a GLP-1/glucagon dual agonist, a linker and hyaluronic acid, MicroRNA compounds and methods for modulating MIR-21 activity and methods for treatment of Alport Syndrome
Lead Pharma Holding BV and SANOFI, filed patent application numbered 201717043245 that is titled as ROR GAMMA (RORY) MODULATORS. The patent has been filed in the field of Chemicals. This Patent Application has been granted as Patent Number 349565. This invention relates to a compound according to a formula wherein A11 — A14 are N or CR11, CR12, CR13, CRI4, respectively, with the proviso that no more than two of the four positions A in A11 – A14 can be simultaneously N; A6, A7, A8, A9, A10 are N or CR6, CR7, CR8, CR9, CR10, respectively.
During the patent examination, the patent examiner raised objections under Section 3(d) and 3(e) of the Indian Patents Act, 1970. It was indicated that the claims were inadmissible under section 3(d) as modulators of RORY compound according to Formula I or a pharmaceutically acceptable salt thereof, is the mere discovery of a new form of a known substance. In the absence of any data depicting the enhancement of the known efficacy of that substance, the claims are not allowable. Further, under Section 3(e) the subject claims were held to be non-patentable as they were directed to a mere admixture resulting only in the aggregation of the properties of the component thereof.
As a response, the Applicant submitted that under Section 3(d) and 3(e) the subject claims were inventive as indicated under the requirement of an Inventive Step. Thus, proving that the same is patentable.
Advocate Rahul Dev is a Patent Attorney & International Business Lawyer practicing Technology, Intellectual Property & Corporate Laws. He is reachable at rd (at) patentbusinesslawyer (dot) com & @rdpatentlawyer on Twitter.
Quoted in and contributed to 50+ national & international publications (Bloomberg, FirstPost, SwissInfo, Outlook Money, Yahoo News, Times of India, Economic Times, Business Standard, Quartz, Global Legal Post, International Bar Association, LawAsia, BioSpectrum Asia, Digital News Asia, e27, Leaders Speak, Entrepreneur India, VCCircle, AutoTech).
Regularly invited to speak at international & national platforms (conferences, TV channels, seminars, corporate trainings, government workshops) on technology, patents, business strategy, legal developments, leadership & management.
